Thin for Now: What Happened to the Chinese Who Injected Semaglutide to Lose Weight
A year into China's weight-loss-injection boom, clinical numbers and user testimonials are converging on an awkward answer: the shots work — about two-thirds of users shed 17 percent of their body weight — but more than half regain it after stopping. Now the drug's popularity has opened a third front: counterfeit and 'recycled' semaglutide circulating outside pharmacies.
When Chinese hospitals began prescribing GLP-1 drugs for obesity, the promise was plain: inject, eat less, shrink. This week's trending question — "what happened to the people who inject semaglutide?" — asked the follow-up, and the answers circulating on Weibo read like a national follow-up examination. The clinical headline, relayed by Red Star News, is that the drug does what it says: over 68 weeks of continued use, users lose on average 17 percent of their body weight and 15.8 centimeters off their waistline, with heavier users losing more. Roughly one in ten, classified as "primary non-responders," barely lose at all.
The awkward number comes next: more than half of users who stop the drug regain the weight. User posts this week put it more bluntly than the clinical trials do. "You got thin — but far more people rebounded than you'd think," one much-shared explainer began, before walking readers through the mechanism: semaglutide is a GLP-1 receptor agonist, a hormone mimic that blunts appetite rather than burning fat. "It doesn't melt fat for you," the post said. "It helps you hold your mouth" (帮你"管住嘴") — Chinese shorthand for keeping yourself from eating. When the drug stops, the appetite returns, and with it the old eating habits the medication had been papering over.
That framing — the drug as a bridge, not a cure — is now the consensus position of the doctors quoted in the coverage. Red Star News's report stresses that rebound is "not drug dependence" but a return of lifestyle patterns, and that people who keep up dietary and exercise changes after stopping can hold or even continue losing. If weight returns within about six months, a doctor may restart the medication; the deeper point, repeated by several posts, is that a growing share of users will be on and off these drugs for years, not through one course.
Users also argue the shots are misunderstood as vanity drugs. "The biggest effect isn't weight loss — it's the metabolic diseases," one post listed: sleep apnea and snoring, arthritis load, fatty liver, type 2 diabetes. That tracks with how China's regulators view the category; this site covered the boom's medical tail risks last month, from muscle loss to gallstones, when the drug was still mostly discussed as a shortcut.
There is a murkier consequence, too. Demand for semaglutide has outrun the legitimate supply chain. State television's investigation into the "recycled drug" trade — reimbursed medication bought back from patients and resold online — named weight-loss injections as one of the worst-hit categories, with storage and handling entirely outside any cold chain. That investigation, which this site covered last week, is the shadow side of this week's follow-up: the same injection that half the country's users will stop and restart is also one that black-market sellers have learned to move. The question "what happened afterwards," in other words, now has a supply-chain answer as well as a medical one.